Correction to: Childs Nerv Syst. 2023 Jun 21. https://doi.org/10.1007/s00381-023-06029-5. Epub ahead of print. PMID: 37344677

In the discussion section of this article we referred to a recent case report that had allegedly demonstrated development of a MPNST during on-going selumetinib therapy. We would like to clarify that the patients described in the cited case report were not on selumetinib therapy but were treated with trametinib. However, this does not change our conclusion that MEK inhibition in general might not be sufficient to prevent malignancy in NF1-PN.